Premier stock to be acquired by Patient Square Capital for $28.25 per share

Premier, Inc. (PINC) will be acquired by an affiliate of Patient Square Capital for approximately $2.6 billion, or $28.25 per share in cash, representing a 10% premium to its recent closing price and a 23.8% premium to its 60-day volume-weighted average price. The transaction, implying an 11x next-twelve-month EV/EBITDA multiple, is expected to close by Q1 2026 and is not subject to financing, reflecting Premier's strong financial performance and potential synergies with Patient Square's existing healthcare portfolio.

Analysis

Premier, Inc. (NASDAQ:PINC) is set to be acquired by Patient Square Capital in a definitive agreement valued at approximately $2.6 billion. The all-cash offer of $28.25 per share represents a 10% premium to its recent closing price and a more substantial 23.8% premium to its 60-day volume-weighted average price. The transaction implies a next-twelve-month EV/EBITDA multiple of 11x, significantly above Premier's three-year historical average of 7.6x, indicating a strong valuation for shareholders. The deal's probability of closing is enhanced by the lack of a financing condition and a sizable $168.6 million reverse termination fee payable by the acquirer. This acquisition follows a period of strong fundamental performance for Premier, which reported net administrative fee revenue of $150.1 million, beating consensus estimates of $136.3 million, and secured a new five-year group purchasing agreement expected to exceed $50 million in annual contract spend. Despite this, analyst sentiment from UBS and Piper Sandler remains Neutral, with price targets of $26.00 and $28.00 respectively, suggesting they view the stock's value as now being anchored to the acquisition price with minimal further upside.

Key Decisions for Investors

• For existing shareholders, the primary consideration is holding the position to capture the remaining arbitrage spread between the current market price and the $28.25 cash offer, factoring in the time value of money until the expected Q1 2026 closing.
• New investors should recognize that upside potential is capped near the $28.25 acquisition price, making this a merger arbitrage play where the main risk is the deal failing to close.
• Investors should monitor progress on regulatory and shareholder approvals, as any negative developments could create downside risk and widen the spread to the offer price.
• The acquisition validates Premier's strong fundamentals; therefore, investors might consider evaluating other companies in the healthcare group purchasing and supply chain services sector for similar investment characteristics.